Full Press Release Details
CZ's Nested Vials are designed to meet the exterior dimensions of glass standard ISO 8362-1 and offer broad compatibility with various aseptic fill-finish equipment available in the market.
EXTON, Pa. , May 29, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST ), a global leader in innovative solutions for injectable drug administration, announced today that it will unveil its new Daikyo Crystal Zenith® (CZ) Nested Vials in Tub at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting taking place in Vancouver, Canada from May 29- June 1 .
Designed to meet the exterior dimensions of glass standard ISO-8362-1, CZ nested vials are a demonstrated containment solution for cell and gene therapies, radiopharmaceuticals, and sensitive molecules. CZ's attributes, such as maintaining container closure integrity down to cryogenic temperatures, superior functional recovery of viral vectors, low particulate specification (2% USP <788>), break resistance, and low risk of chemical interaction, make it ideal for advanced therapies. CZ vials have demonstrated to be effective in safely storing gene therapy drugs and meeting the packaging demands from preclinical to commercial phases.
"West has been at the forefront of pharmaceutical packaging for over 100 years and is the market leader for containment solutions for cell and gene therapy treatments," said Cindy Reiss-Clark, Chief Commercial Officer at West. "This new offering expands the CZ platform to provide packaging configuration options for flexible filling solutions of sensitive molecules."
Product Specifications
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.
Headquartered in Exton, Pennsylvania , West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST ) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com .
West and the diamond logo and NovaPure are registered trademarks of West Pharmaceutical Services, Inc.
Crystal Zenith and PLASCAP are registered trademarks of Daikyo Seiko, Ltd.
Tyvek® is a registered trademark of DuPont de Nemours, Inc. or its affiliate.
Crystal Zenith technology is licensed from Daikyo Seiko, Ltd.
© 2024 West Pharmaceutical Services, Inc.